Skip to main content

Table 3 The performance indicators of screening, stratified by the age, sex, and the brands of tests

From: Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study

Brands of PG test †

Positive predictive value (%)*

Detection rate (per 1000)*

Atrophic gastritis

Intestinal metaplasia

Atrophic gastritis

Intestinal metaplasia

Test 1

Test 2

Test 1 + 2

Test 1

Test 2

Test 1 + 2

Test 1

Test 2

Test 1 + 2

Test 1

Test 2

Test 1 + 2

Male

 30–49 years

10.0

10.0

6.7

10.0

11.1

6.7

1.2

1.2

1.2

1.2

1.2

1.2

 ≥ 50 years

20.6

19.4

16.3

32.3

28.0

25.6

4.2

4.2

4.2

6.6

6.6

6.6

Subtotal

18.2

17.4

13.8

27.3

26.7

20.7

3.2

3.2

3.2

4.8

4.8

4.8

Female

 30–49 years

11.1

12.5

8.3

11.1

11.1

7.7

1.0

1.0

1.0

1.0

1.0

1.0

 ≥ 50 years

14.8

15.4

11.4

22.2

15.4

20.0

2.5

2.5

2.5

3.7

2.5

4.4

Subtotal

13.8

14.7

10.6

19.4

14.3

16.7

1.9

1.9

1.9

2.7

1.9

3.1

Both sexes

 30–49 years

10.5

11.1

7.4

10.5

11.1

7.1

1.1

1.1

1.1

1.1

1.1

1.1

 ≥ 50 years

18.0

17.7

14.1

27.9

24.2

23.1

3.4

3.4

3.4

5.2

4.6

5.5

Total

16.3

16.3

12.4

23.8

21.3

18.9

2.5

2.5

2.5

3.7

3.3

3.9

  1. PG = pepsinogen; Test 1 = GastroPanel (Biohit HealthCare, Helsinki, Finland); Test 2 = LZ-Test (Eiken Chemical Co., Ltd, Tokyo, Japan); Test 1 + 2 = two tests in parallel
  2. *Positive predictive value was defined as the number of participants with premalignant lesions/ the number of participants positive to PG tests having attended an upper endoscopy. Detection rate was defined as the number of participants with premalignant lesions detected/ the number of participants having received the PG testing
  3. †None reaches the significant P level of < 0.05 in the comparison between Test 1 and Test 2
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us